189 related articles for article (PubMed ID: 23169362)
1. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
Ghorbani A; Omidvar B; Beladi-Mousavi SS; Lak E; Vaziri S
Nefrologia; 2012; 32(6):790-6. PubMed ID: 23169362
[TBL] [Abstract][Full Text] [Related]
2. Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Navarro JF; Mora C; Muros M; García J
J Am Soc Nephrol; 2005 Jul; 16(7):2119-26. PubMed ID: 15917336
[TBL] [Abstract][Full Text] [Related]
3. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Lin SL; Chen YM; Chiang WC; Wu KD; Tsai TJ
Am J Kidney Dis; 2008 Sep; 52(3):464-74. PubMed ID: 18617301
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus.
Aminorroaya A; Janghorbani M; Rezvanian H; Aminian T; Gharavi M; Amini M
Nephron Clin Pract; 2005; 99(3):c73-7. PubMed ID: 15665549
[TBL] [Abstract][Full Text] [Related]
5. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
[TBL] [Abstract][Full Text] [Related]
6. Will the addition of pentoxifylline reduce proteinuria in patients with diabetic glomerulosclerosis refractory to maximal doses of both an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker?
Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
J Nephrol; 2007; 20(4):410-6. PubMed ID: 17879206
[TBL] [Abstract][Full Text] [Related]
7. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
8. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
[TBL] [Abstract][Full Text] [Related]
10. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy.
Roozbeh J; Banihashemi MA; Ghezlou M; Afshariani R; Salari S; Moini M; Sagheb MM
Ren Fail; 2010 Jan; 32(2):172-8. PubMed ID: 20199178
[TBL] [Abstract][Full Text] [Related]
11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
Vogt L; Kocks MJ; Laverman GD; Navis G
Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus.
Rasi Hashemi S; Noshad H; Tabrizi A; Mobasseri M; Tayebi Khosroshahi H; Heydarnejad M; Khalaj MR; Aghamohammadzadeh N
Iran J Kidney Dis; 2012 Jan; 6(1):39-43. PubMed ID: 22218118
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline for renoprotection in diabetic nephropathy: the PREDIAN study. Rationale and basal results.
Navarro-González JF; Muros M; Mora-Fernández C; Herrera H; Meneses B; García J
J Diabetes Complications; 2011; 25(5):314-9. PubMed ID: 21144773
[TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.
Chen YM; Lin SL; Chiang WC; Wu KD; Tsai TJ
Kidney Int; 2006 Apr; 69(8):1410-5. PubMed ID: 16541021
[TBL] [Abstract][Full Text] [Related]
15. Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients.
Guerrero-Romero F; Rodríguez-Morán M; Paniagua-Sierra JR; García-Bulnes G; Salas-Ramírez M; Amato D
Clin Nephrol; 1995 Feb; 43(2):116-21. PubMed ID: 7736673
[TBL] [Abstract][Full Text] [Related]
16. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
[TBL] [Abstract][Full Text] [Related]
17. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.
McCormick BB; Sydor A; Akbari A; Fergusson D; Doucette S; Knoll G
Am J Kidney Dis; 2008 Sep; 52(3):454-63. PubMed ID: 18433957
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
19. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
20. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
